Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.

Optimizing SG&A: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Zoetis Inc. and Sarepta Therapeutics, Inc. have taken distinct paths in optimizing these costs.

From 2014 to 2023, Zoetis Inc. consistently maintained higher SG&A expenses, peaking at approximately $2.15 billion in 2023. Despite this, their expenses grew at a modest rate of around 31% over the decade. In contrast, Sarepta Therapeutics, Inc. saw a staggering increase of over 870% in SG&A expenses, from $49 million in 2014 to nearly $482 million in 2023.

This data highlights Zoetis's stable approach to cost management, while Sarepta's rapid growth reflects its aggressive expansion strategy. Understanding these trends offers valuable insights into how these companies navigate financial challenges in a dynamic market.